公开(公告)号：US20210223249A1

公开(公告)日：2021-07-22

申请号：US15999378

申请日：2017-02-16

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

Inventor： Ptrick TAN ,  Wen Fong OOl

IPC: G01N33/574 ,  G01N33/53 ,  G01N33/563

Abstract: The present invention relates to a method for determining the presence or absence of at least one super-enhancer in a cancerous biological sample based on signal intensity of the histone modification H3K27ac. The present invention also relates to a method for determining the prognosis of cancer in a subject, a method of determining the susceptibility of a subject to cancer or a gastrointestinal disease and a method of predicting cancer cell survival or cancer cell viability by determining the presence or absence of at least one super-enhancer. The present invention also relates to inhibitors of CDX2 and/or HNF4α, such as metformin, and use thereof for modulating the activity of a super-enhancer.